| |
[摘要]：Although traditional chemotherapeutic agents have saved thousands of lives over the years and delayed tumor progression, they have limited efficacy due to toxicity and lack of tumor cell selectivity. Recently some of the more promising anticancer therapy approaches tested and proven in clinical studies have used a combinatorial approach Of using new molecularly targeted agents with standard therapies. In this regard, inhibition of angiogenesis represents a new approach to cancer therapy. To date, many antiangiogenic agents have been developed and are in different stages of clinical development. Targeting tumor cell-associated endothelial cells may represent a potential powerful adjunct to traditional cancer therapy. In this review, we provide an overview of different approaches involved in discovery and development of anti-angiogenic agents and discuss the clinical impact of these agents. Finally, we present and summarize some of the emerging concepts such as resistance to anti-angiogenic drugs, antiangiogenic therapy-related toxicity, and integrated treatment modalities. Drug Dev Res 69:340-351, 2008. (c) 2008 Wiley-Liss, Inc. |
|
